MCID: RNL003
MIFTS: 58

Renal Clear Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Renal Clear Cell Carcinoma

MalaCards integrated aliases for Renal Clear Cell Carcinoma:

Name: Renal Clear Cell Carcinoma 12 51 14
Clear-Cell Metastatic Renal Cell Carcinoma 12 69
Conventional Renal Cell Carcinoma 12 69
Clear Cell Carcinoma of Kidney 12 28
Clear Cell Renal Cell Adenocarcinoma 55
Conventional Renal Cell Carcinoma 12
Clear Cell Renal Cell Carcinoma 55
Clear Cell Kidney Carcinoma 12
Clear Cell Renal Carcinoma 55
Ccrcc 55

Classifications:

Orphanet: 55  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 41 D002292
NCIt 46 C4033
Orphanet 55 ORPHA319276
UMLS via Orphanet 70 C0279702
ICD10 via Orphanet 33 C64

Summaries for Renal Clear Cell Carcinoma

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

MalaCards based summary : Renal Clear Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to clear cell renal cell carcinoma and hypoxia, and has symptoms including flank pain An important gene associated with Renal Clear Cell Carcinoma is PBRM1 (Polybromo 1), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Sunitinib and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and lung, and related phenotypes are Increased Nanog expression and Increased Nanog expression

Related Diseases for Renal Clear Cell Carcinoma

Diseases in the Renal Clear Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Cell Carcinoma 4

Diseases related to Renal Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 clear cell renal cell carcinoma 32.1 CA9 HIF1A KDR OGG1 PBRM1 SETD2
2 hypoxia 30.7 CA9 HIF1A MTOR VEGFA VHL
3 oncocytoma 30.5 KRT7 MME MUC1 VIM
4 hemangioblastoma 30.5 MUC1 VEGFA VHL
5 adenocarcinoma 30.5 BIRC5 KDR MUC1 VEGFA
6 spindle cell carcinoma 30.5 KRT7 MUC1 VIM
7 lung cancer 28.6 BIRC5 CA9 FHIT HIF1A KDR KRT7
8 renal cell carcinoma, nonpapillary 26.8 CA9 ELOB ELOC FHIT HIF1A HNF1A
9 hereditary conventional renal cell carcinoma 12.2
10 endolymphatic sac tumor 10.7 KRT7 VHL
11 fumarate hydratase deficiency 10.7 HIF1A VHL
12 pancreatic serous cystadenoma 10.6 KRT7 VEGFA VHL
13 epithelioid hemangioendothelioma 10.6 KDR VEGFA VHL
14 nodular prostate 10.6 CA9 HIF1A KDR
15 balloon cell malignant melanoma 10.6 KRT7 MME
16 angiokeratoma circumscriptum 10.6 KDR VEGFA
17 renal pelvis carcinoma 10.6 CA9 KRT7 VEGFA
18 acute mountain sickness 10.6 HIF1A VEGFA VHL
19 cervical adenoma malignum 10.6 KRT7 MME
20 vulvar intraepithelial neoplasia 10.6 BIRC5 KRT7
21 intravascular papillary endothelial hyperplasia 10.6 HIF1A VEGFA VIM
22 limb ischemia 10.6 HIF1A KDR VEGFA
23 middle ear adenoma 10.6 KRT7 MUC1
24 exudative vitreoretinopathy 1 10.6 HIF1A KDR VEGFA
25 retinal ischemia 10.6 HIF1A SETD2 VEGFA
26 nephrogenic adenofibroma 10.6 CA9 KRT7 MME
27 pancreatic ductal carcinoma 10.6 KRT7 MUC1 VEGFA
28 large intestine adenocarcinoma 10.6 KRT7 MTOR
29 adenomyoma 10.6 KRT7 MME MUC1
30 endosalpingiosis 10.6 KRT7 MUC1
31 mucinous tubular and spindle renal cell carcinoma 10.6 KRT7 MME MUC1
32 glandular cystitis 10.6 KRT7 MUC1
33 parachordoma 10.6 KRT7 MUC1 VIM
34 malignant mixed mullerian tumor 10.6 KRT7 MUC1 VIM
35 malignant ovarian surface epithelial-stromal neoplasm 10.6 KRT7 MUC1 VEGFA
36 ovary epithelial cancer 10.6 KRT7 MUC1 VEGFA
37 nodular hidradenoma 10.6 KRT7 MUC1 VIM
38 transitional meningioma 10.6 HIF1A MUC1
39 cystadenofibroma 10.5 KRT7 MME MUC1
40 malignant peritoneal mesothelioma 10.5 BIRC5 MUC1 VIM
41 eccrine porocarcinoma 10.5 KRT7 MUC1 VIM
42 kidney benign neoplasm 10.5 KRT7 MME MTOR
43 retinal hemangioblastoma 10.5 CA9 HIF1A VEGFA VHL
44 pancreatic mucinous cystadenoma 10.5 KRT7 MME MUC1
45 monophasic synovial sarcoma 10.5 KRT7 MUC1 VIM
46 hidradenoma 10.5 KRT7 MUC1 VIM
47 mucinous cystadenocarcinoma 10.5 KRT7 MUC1 VIM
48 spiradenoma 10.5 KRT7 MUC1 VIM
49 dermoid cyst 10.5 KRT7 MUC1 VIM
50 benign mesothelioma 10.5 KRT7 MUC1 VIM

Graphical network of the top 20 diseases related to Renal Clear Cell Carcinoma:



Diseases related to Renal Clear Cell Carcinoma

Symptoms & Phenotypes for Renal Clear Cell Carcinoma

UMLS symptoms related to Renal Clear Cell Carcinoma:


flank pain

GenomeRNAi Phenotypes related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.78 SETD2 VEGFA BIRC5 ELOB
2 Increased Nanog expression GR00371-A-2 9.78 SETD2 VEGFA VHL
3 Increased Nanog expression GR00371-A-3 9.78 BIRC5
4 Increased Nanog expression GR00371-A-4 9.78 SETD2 VEGFA
5 Increased Nanog expression GR00371-A-5 9.78 SETD2 VEGFA VHL BIRC5 ELOB MTOR

MGI Mouse Phenotypes related to Renal Clear Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 MTOR OGG1 HIF1A HNF1A KDR KRT7
2 hematopoietic system MP:0005397 10.13 HIF1A OGG1 PBRM1 KDR SETD2 BIRC5
3 homeostasis/metabolism MP:0005376 10.1 HIF1A OGG1 HNF1A SETD2 KDR BIRC5
4 embryo MP:0005380 10.02 HIF1A PBRM1 SETD2 KDR BIRC5 MTOR
5 immune system MP:0005387 9.97 HIF1A OGG1 PBRM1 KDR BIRC5 MME
6 liver/biliary system MP:0005370 9.56 HIF1A OGG1 HNF1A PBRM1 KDR MME
7 mortality/aging MP:0010768 9.44 FHIT OGG1 HIF1A HNF1A PBRM1 KDR

Drugs & Therapeutics for Renal Clear Cell Carcinoma

Drugs for Renal Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
2
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 110942-02-4, 85898-30-2
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
4
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
5 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
6 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
13 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
18
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
19
Iodine Approved, Investigational Phase 3 7553-56-2 807
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
21
Everolimus Approved Phase 3,Phase 1,Phase 2 159351-69-6 6442177
22
Sirolimus Approved, Investigational Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
23
Axitinib Approved, Investigational Phase 3,Phase 1,Phase 2 319460-85-0 6450551
24 cadexomer iodine Phase 3
25 interferons Phase 3,Phase 2,Phase 1
26 Micronutrients Phase 3,Phase 1,Phase 2
27 Mitogens Phase 3,Phase 2,Phase 1
28 Trace Elements Phase 3,Phase 1,Phase 2
29 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
31 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
32 Immunoconjugates Phase 3,Phase 1
33 Antifungal Agents Phase 3,Phase 1,Phase 2
34 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
35 Anti-Infective Agents, Local Phase 3
36 Interferon-alpha Phase 3,Phase 2,Phase 1
37 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
39 tyrosine Nutraceutical Phase 3,Phase 1,Phase 2
40
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
41
Tinzaparin Approved Phase 1, Phase 2 9041-08-1, 9005-49-6 25244225
42
Dalteparin Approved Phase 1, Phase 2 9005-49-6
43
Ethanol Approved Phase 2 64-17-5 702
44
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
45
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
46
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
47
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
48
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
49
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
50
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 185)

# Name Status NCT ID Phase Drugs
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
3 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
4 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
5 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
6 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
7 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
8 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
9 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
10 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
11 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
12 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
13 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Active, not recruiting NCT01599754 Phase 3 Axitinib;Placebo
14 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
15 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
16 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3 Everolimus
17 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
18 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
19 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
20 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
21 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Unknown status NCT01896271 Phase 2 IL-2
22 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
23 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
24 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
25 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
26 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
27 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
28 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
29 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
30 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
31 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
32 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
33 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Completed NCT00323739 Phase 2 bevacizumab;RAD001
34 Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus Completed NCT01715935 Phase 2 Everolimus
35 Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
36 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
37 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Completed NCT00408902 Phase 2 tandutinib
38 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
39 Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer Completed NCT00278174 Phase 2
40 Rotating Pazopanib and Everolimus to Avoid Resistance Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
41 Bryostatin 1 In Treating Patients With Progressive Kidney Cancer Completed NCT00005056 Phase 2 bryostatin 1
42 Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Completed NCT00392821 Phase 1, Phase 2 Sorafenib;RAD001
43 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
44 Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01158222 Phase 2 sunitinib malate
45 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
46 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy Completed NCT01141569 Phase 2 Gamma-Secretase Inhibitor RO4929097
47 Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01024205 Phase 2 sunitinib malate
48 Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Completed NCT00126594 Phase 2 Sorafenib Tosylate
49 CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00112840 Phase 1, Phase 2 CCI-779;Bevacizumab
50 RPI.4610 in Treating Patients With Metastatic Kidney Cancer Completed NCT00021021 Phase 2

Search NIH Clinical Center for Renal Clear Cell Carcinoma

Genetic Tests for Renal Clear Cell Carcinoma

Genetic tests related to Renal Clear Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 28

Anatomical Context for Renal Clear Cell Carcinoma

MalaCards organs/tissues related to Renal Clear Cell Carcinoma:

38
Kidney, Endothelial, Lung, Thyroid, T Cells, Liver, Bone

Publications for Renal Clear Cell Carcinoma

Articles related to Renal Clear Cell Carcinoma:

(show top 50) (show all 171)
# Title Authors Year
1
Re: Serum tissue factor as biomarker for renal clear cell carcinoma: a comment. ( 29135416 )
2018
2
MicroRNA-645 promotes cell metastasis and proliferation of renal clear cell carcinoma by targeting GK5. ( 29131260 )
2017
3
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. ( 28984208 )
2017
4
Analysis of healthy and tumour DNA methylation distributions in kidney-renal-clear-cell-carcinoma using Kullback-Leibler and Jensen-Shannon distance measures. ( 28518060 )
2017
5
Identification of prognostic genes in kidney renal clear cell carcinoma by RNAa89seq data analysis. ( 28260099 )
2017
6
Renal clear cell carcinoma metastasis to the breast ten years after nephrectomy: a case report and literature review. ( 29096639 )
2017
7
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-I^-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma. ( 28668830 )
2017
8
Preliminary Application of WCX Magnetic Bead-Based Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry in Analyzing the Urine of Renal Clear Cell Carcinoma. ( 29301600 )
2017
9
Serum tissue factor as a biomarker for renal clear cell carcinoma. ( 28727370 )
2017
10
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report. ( 28072710 )
2017
11
Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma. ( 28969028 )
2017
12
Renal clear cell carcinoma: diffusion tensor imaging diagnostic accuracy and correlations with clinical and histopathological factors. ( 28330685 )
2017
13
Orellanine specifically targets renal clear cell carcinoma. ( 29207627 )
2017
14
Monoexponential, biexponential, and stretched exponential diffusion-weighted imaging models: Quantitative biomarkers for differentiating renal clear cell carcinoma and minimal fat angiomyolipoma. ( 27859853 )
2016
15
Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma. ( 28029655 )
2016
16
PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. ( 27100670 )
2016
17
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. ( 27484998 )
2016
18
Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis. ( 27362805 )
2016
19
Metastasis of Renal Clear Cell Carcinoma to Thyroid Gland Mimicking Adenomatous Goiter. ( 28096905 )
2016
20
Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma. ( 27110129 )
2016
21
Unusual Ultrasound Presentation of Testicular Metastasis from Renal Clear Cell Carcinoma. ( 27746886 )
2016
22
Screening for the Key lncRNA Targets Associated With Metastasis of Renal Clear Cell Carcinoma. ( 26765468 )
2016
23
Renal clear cell carcinoma metastasis to salivary glands - a series of 9 cases: clinico-pathological study. ( 27179273 )
2016
24
Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma. ( 27092013 )
2016
25
Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy. ( 27818943 )
2016
26
Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. ( 26992212 )
2016
27
Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma. ( 26909952 )
2016
28
Clinical significance of changes of expression of the Wnt/I^-catenin signaling pathway in renal clear cell carcinoma. ( 27981554 )
2016
29
Metastases of renal clear cell carcinoma to ovary--case report and review of the literature. ( 26050366 )
2015
30
An atypical metastasis of renal clear cell carcinoma to the upper lip: a case report. ( 25579020 )
2015
31
A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma. ( 26539246 )
2015
32
Renal Clear Cell Carcinoma Acrometastasis. An Unusual Terminal Condition. ( 26078530 )
2015
33
High selectivity of PI3KI^ inhibitors in SETD2-mutated renal clear cell carcinoma. ( 26537074 )
2015
34
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. ( 26312386 )
2015
35
Differentiation of renal oncocytoma and renal clear cell carcinoma using relative CT enhancement ratio. ( 25591558 )
2015
36
Bilateral sporadic synchronous renal clear-cell carcinoma treated by bilateral partial laparoscopic nephrectomy: Report of two cases. ( 26530869 )
2015
37
Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. ( 26464696 )
2015
38
Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma. ( 25778315 )
2015
39
Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-I_B signaling in human renal clear cell carcinoma. ( 26617834 )
2015
40
microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes. ( 25758424 )
2015
41
Image of the month: Gastric metastasis of renal clear cell carcinoma. ( 25713859 )
2015
42
Netrin-1: The new tumor markers in renal clear cell carcinoma. ( 26194836 )
2015
43
Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. ( 25592567 )
2015
44
Renal clear cell carcinoma with thyroid and parotid metastases: A case report. ( 26622899 )
2015
45
Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway. ( 26884975 )
2015
46
Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. ( 26506913 )
2015
47
Expression and Prognostic Role of MEKK3 and pERK in Patients with Renal Clear Cell Carcinoma. ( 25824786 )
2015
48
A unique presentation of a renal clear cell carcinoma with atypical metastases. ( 25911241 )
2015
49
Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. ( 24454902 )
2014
50
Identification of genes and pathways involved in kidney renal clear cell carcinoma. ( 25559354 )
2014

Variations for Renal Clear Cell Carcinoma

ClinVar genetic disease variations for Renal Clear Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
2 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
3 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387

Cosmic variations for Renal Clear Cell Carcinoma:

9 (show top 50) (show all 1100)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 18
2 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 18
3 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 18
4 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 18
5 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 18
6 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 18
7 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 18
8 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 18
9 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 18
10 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 18
11 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 18
12 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 18
13 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 13
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 13
15 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 13
16 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 13
17 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 13
18 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 13
19 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 13
20 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 13
21 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 13
22 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 13
23 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13
24 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13
25 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 13
26 COSM18132 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463+2T>C p.? 13
27 COSM30221 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>A p.I109N 13
28 COSM17721 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>T p.P81S 13
29 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 13
30 COSM17789 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>A p.Y175* 13
31 COSM14376 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>A p.? 13
32 COSM14309 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.478G>A p.E160K 13
33 COSM14408 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.485G>A p.C162Y 13
34 COSM17612 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.481C>T p.R161* 13
35 COSM1169455 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 13
36 COSM17928 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>C p.V155L 13
37 COSM17948 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.172C>A p.R58R 13
38 COSM25678 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.563T>C p.L188P 13
39 COSM18379 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.505C>T p.L169L 13
40 COSM3734681 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.511A>T p.K171* 13
41 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 13
42 COSM17934 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.452T>C p.I151T 13
43 COSM14363 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.458T>C p.L153P 13
44 COSM17651 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.445G>C p.A149P 13
45 COSM34019 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.361G>T p.D121Y 13
46 COSM14372 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>A p.S68* 13
47 COSM144717 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.287A>C p.Q96P 13
48 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 13
49 COSM17839 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.317G>C p.G106A 13
50 COSM3727795 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.385C>A p.L129M 13

Expression for Renal Clear Cell Carcinoma

Search GEO for disease gene expression data for Renal Clear Cell Carcinoma.

Pathways for Renal Clear Cell Carcinoma

Pathways related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13 CA9 ELOB ELOC HIF1A MTOR VEGFA
2 12.7 BIRC5 ELOB ELOC HIF1A MTOR VEGFA
3
Show member pathways
12.29 ELOB ELOC HIF1A MTOR VEGFA VHL
4 12.14 HIF1A KDR MTOR VEGFA
5 11.78 BIRC5 HIF1A MUC1 VEGFA VIM
6
Show member pathways
11.72 HIF1A KDR VEGFA VHL
7 11.69 CA9 HIF1A KDR
8 11.51 CA9 HIF1A VEGFA
9 11.43 ELOB ELOC HIF1A MTOR VEGFA VHL
10 11.41 BIRC5 HIF1A HNF1A VEGFA
11 11.39 ELOB ELOC HIF1A VEGFA VHL
12 11.24 BIRC5 HIF1A VEGFA
13 11.03 HIF1A KDR VEGFA
14 10.63 ELOB ELOC HIF1A VHL
15 10.55 ELOB ELOC KDR VEGFA VHL
16 10.51 ELOB ELOC
17 10.5 HIF1A VEGFA

GO Terms for Renal Clear Cell Carcinoma

Cellular components related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 BIRC5 CA9 ELOB ELOC FHIT HIF1A
2 elongin complex GO:0070449 9.16 ELOB ELOC
3 VCB complex GO:0030891 8.96 ELOB VHL

Biological processes related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.78 HIF1A KDR SETD2 VEGFA
2 negative regulation of gene expression GO:0010629 9.76 HIF1A KDR VEGFA VHL
3 transcription elongation from RNA polymerase II promoter GO:0006368 9.7 ELOB ELOC SETD2
4 negative regulation of apoptotic process GO:0043066 9.63 BIRC5 HIF1A KDR OGG1 VEGFA VHL
5 vasculogenesis GO:0001570 9.61 KDR SETD2 VEGFA
6 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.55 HIF1A VEGFA
7 cell migration involved in sprouting angiogenesis GO:0002042 9.54 KDR VEGFA
8 growth GO:0040007 9.51 MTOR VEGFA
9 positive regulation of positive chemotaxis GO:0050927 9.49 KDR VEGFA
10 positive regulation of blood vessel endothelial cell migration GO:0043536 9.43 HIF1A KDR VEGFA
11 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.37 KDR VEGFA
12 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.32 HIF1A VEGFA
13 positive regulation of endothelial cell proliferation GO:0001938 9.26 HIF1A KDR MTOR VEGFA
14 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.1 CA9 ELOB ELOC HIF1A VEGFA VHL
15 regulation of transcription, DNA-templated GO:0006355 10.1 BIRC5 ELOB ELOC FHIT HIF1A HNF1A

Molecular functions related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 BIRC5 CA9 ELOB ELOC FHIT HIF1A

Sources for Renal Clear Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....